Bruker reported Q4-25 revenues of $977.2 million, which was flat year-over-year, and GAAP diluted EPS of $0.10. For the full year 2025, revenues were $3.44 billion, up ~2% year-over-year, with a GAAP diluted loss per share of $(0.15). The company initiated FY26 guidance with expected revenue growth of 4% to 5% and non-GAAP EPS growth of 15% to 17%.
Q4-25 revenues were $977.2 million, showing flat year-over-year performance but a ~5% organic decrease.
GAAP diluted EPS for Q4-25 was $0.10, while non-GAAP diluted EPS was $0.59.
Full year 2025 revenues reached $3.44 billion, an increase of ~2% year-over-year, with a GAAP diluted loss per share of $(0.15).
Bruker provided FY26 guidance, projecting revenues of $3.57 to $3.60 billion and non-GAAP EPS of $2.10 to $2.15.
Bruker expects FY26 revenues of $3.57 to $3.60 billion, representing 4% to 5% year-over-year reported revenue growth, and non-GAAP EPS of $2.10 to $2.15, an increase of 15% to 17% year-over-year.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance